Company Analysis
Sign in

Emergent Biosolutions, Inc. (EBS)

NYSE: EBS · Pharmaceutical Preparations · Gaithersburg, MD · filing with the SEC since 2006
Full chart Alerts Compare
Grade4.6
◀ Past 4.6● Present 5.4▶ Future 3.5
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

28 patents granted to the 9 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Emergent Biosolutions, Inc.’s names, not what it holds today.

Patents granted
28
26 utility, 2 design, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and none in 2023
Applications published
34
1 of them in 2025
Names they are printed under
9
a subsidiary, its own name
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name9 counted
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. a subsidiary
US, as the owner printed on each patent
22 granted
15 published
Emergent Product Development Gaithersburg Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
EMERGENT BIOSOLUTIONS CANADA INC. a subsidiary
CA, as the owner printed on each patent
2 granted
2 published
Emergent BioSolutions Inc. its own name
US, as the owner printed on each patent
1 granted
2 published
EMERGENT BIODEFENSE OPERATIONS LANSING LLC a subsidiary
US, as the owner printed on each patent
2 granted
0 published
EMERGENT BIODEFENSE OPERATIONS LANSING LLC a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
EMERGENT TRAVEL HEALTH INC. a subsidiary
US, as the owner printed on each patent
1 granted
1 published
Emergent BioSolutions its own name
named as the applicant on its applications, in US
0 granted
2 published
Emergent BioSolutions Canada Inc. a subsidiary
named as the applicant on its applications, in CA
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,485,131Formulations of brincidofovirPharmaceuticalsEMERGENT BIODEFENSE OPERATIONS LANSING LLC
Apr 30, 202411,969,465Toxoplasma gondii vaccines and their usePharmaceuticalsEMERGENT TRAVEL HEALTH INC.
Feb 27, 202411,912,667Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereofOrganic fine chemistryEMERGENT BIODEFENSE OPERATIONS LANSING LLC
Oct 4, 2022D965,767AutoinjectorEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Jul 12, 2022D957,624AutoinjectorEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Dec 31, 201910,517,8652-pyridone antimicrobial compositionsPharmaceuticalsEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Jul 23, 201910,357,559Temperature stable vaccine formulationsPharmaceuticalsEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Dec 18, 201810,155,021Antimicrobial 4-oxoquinolizinesPharmaceuticalsEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Nov 6, 201810,117,933Antibodies against Clostridium difficilePharmaceuticalsEMERGENT BIOSOLUTIONS CANADA INC.
Sep 5, 20179,751,919Antimicrobial compositions comprising a hyaluronic acid binding peptide and a β-lactam antibioticPharmaceuticalsEMERGENT BIOSOLUTIONS CANADA INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 19, 20252025/0197372DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORSOrganic fine chemistryEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Nov 14, 20242024/0374709VACCINE COMPOSITIONSPharmaceuticalsEmergent Product Development Gaithersburg Inc.
Jul 4, 20242024/0217938MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS AND METHODS OF SYNTHESIS THEREOFOrganic fine chemistryEMERGENT BIODEFENSE OPERATIONS LANSING LLC
Jul 4, 20242024/0216280MICROSPHERE FORMULATIONS COMPRISING NALMEFENE ANDMETHODS FOR MAKING AND USING THE SAMEPharmaceuticalsEmergent Product Development Gaithersburg Inc.
May 30, 20242024/0174619VALIOLAMINE DERIVATIVES AS GLUCOSIDASE INHIBITORSOrganic fine chemistryEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Mar 14, 20242024/0082198STABILIZED ALKYL NITRITE COMPOSITIONSOrganic fine chemistryEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Feb 15, 20242024/0052020HYPERIMMUNE GLOBULIN FORMULATIONSPharmaceuticalsEMERGENT BIOSOLUTIONS CANADA INC.
Oct 12, 20232023/0321354AUTOINJECTOR FOR ADMINISTRATION OF MEDICATIONSMedical technologyEmergent Product Development Gaithersburg Inc.
Jul 6, 20232023/0210873FORMULATIONS OF BRINCIDOFOVIRPharmaceuticalsEMERGENT BIODEFENSE OPERATIONS LANSING LLC · patent 12,485,131 granted from it
May 18, 20232023/0149388OPIOID ANTAGONIST FORMULATIONSPharmaceuticalsEmergent Product Development Gaithersburg Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 4 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EBS · research, not advice